ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States

ImmunityBio acquiring U.S. rights to Tokyo strain of BCG (IBRX:NASDAQ)

ImmunityBio (IBRX) stock is in focus as the firm licenses U.S. rights to Tokyo-172 BCG for bladder cancer after Phase 3 data showed its potential. Read more here.

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States

Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 randomized clinical trial demonstrating

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities. The post ImmunityBio’s BCG Agreement Puts Mon…

New deal targets decade-long bladder cancer BCG shortage in U.S.

Chronic U.S. BCG shortages for bladder cancer spur an exclusive Tokyo-172 supply deal, with ImmunityBio leading U.S. approval bid and commercialization.